$XBI $127 +2%
Covid Updates
$VIR +13% GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients. source
$ALT +9% Altimmune Demonstrates Strong Neutralization Of South African Variant In Preclinical Study Of Intranasal AdCOVID™. source
Pipeline Updates
$LEGN +5% U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma. source
$MYOV +5% Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids. source
$GLYC +5% GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation. source
$APVO +1% Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia. source
$PTCT +1% PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia. source
$RVNC +6% Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection. source
$PCRX -5% PACIRA BIOSCIENCES ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 STRIDE STUDY EVALUATING EXPAREL AS A LOWER EXTREMITY NERVE BLOCK. source
$VTGN -9% VistaGen Therapeutics Initiates PALISADE Phase 3 Trial of PH94B in Social Anxiety Disorder. source
$KMPH -1% KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status. source
$CFRX +5% CONTRAFECT ANNOUNCES MULTIPLE PUBLICATIONS ON EXEBACASE, INCLUDING FIRST MANUSCRIPT ON LOCAL ADMINISTRATION OF LYSIN FOR POTENTIAL TREATMENT OF PROSTHETIC JOINT INFECTIONS. source
$ADCT +4% ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology. source
$CCCC +8% C4 THERAPEUTICS TO ADVANCE CFT8919, A SELECTIVE DEGRADER OF EGFR L858R, INTO IND-ENABLING STUDIES. source
$EBS +1% Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate. source
Posted by DV
Comentarios